Time to Buy This Beaten-Down Sector

Calling all contrarian investors...‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

View in browser SPONSORED Gold in a portfolio is the best way to combat inflation in 2022. Gold's explosion in 2020 and subsequent pullback in 2021 has presented a REAL opportunity for investors. If you're serious about owning gold - and getting it while it's still less expensive - you absolutely must act now! Take advantage of our sale on Dealer's Choice 1 oz. Gold Bars as low as $59 over Spot, plus receive a FREE 1 oz. Silver American Eagle with ANY purchase. Call 1-800-831-0007. Clients have been trusting ASI to help you KEEP WHAT'S YOURS for 40 years! MARKET TRENDS Play the Coming Rebound in the Biotech Sector Jody Chudley, Contributing Analyst, The Oxford Club As a contrarian, I love nothing more than seeing an entire sector of stocks fall deeply out of favor. When sellers overwhelm buyers, fundamentals are forgotten and stocks can become incredibly mispriced. Today, my contrarian focus is locked in on the biotech sector. Investors are fleeing biotech stocks. In 2021, the SPDR S&P Biotech ETF (NYSE: XBI), an exchange-traded fund (ETF), dropped 35% from its February peak through the end of the year. After that dismal performance, many folks thought that 2022 would be a rebound year for biotech stocks. SPONSORED $10 Tech Stock Multiplies Profit 12-Fold in One Year! Groundbreaking new tech is being hailed as a "technological tour de force." And one company is seeing profits pour in. See why Samsung, Tesla and Apple are all reportedly now working with this $10 stock. Instead, the sell-off has intensified. The SPDR S&P Biotech ETF has already dropped another 20% this year. All in all, the equal-weighted ETF has been cut in half since it peaked almost exactly one year ago today. Talk about a chart only a contrarian could love! Remember, after a 50% decline, a security needs to increase 100% to get back to where it started. Even if that takes five to seven years, investors buying today in advance of the recovery would be well rewarded. So... why have biotech stocks been beaten down so relentlessly? Click to Read More... MORE FROM WEALTHY RETIREMENT A 5.8% Yield That Will Be Volatile Smaller Companies Have Been Mauled by the Bear The Safe, Steady Path to Your Dream Retirement Top Ways to Trade in Down Markets Facebook Twitter Email Share Push Alert SPONSORED Palm Beach Millionaire Reveals His Biggest Dividend Secrets He's Doing It Completely FREE OF CHARGE Right Here. You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2022 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 1.800.589.3430 | International: +1.443.353.4334 | Fax: 1.410.329.1923 Oxfordclub.com The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.